Non-small cell lung cancer (NSCLC) is a heterogeneous disease that accounts for 85% of lung cancer diagnoses, accompanied by various alterations in known oncogenes including EGFR, ALK, ROS and MET. MET exon 14 skipping (METex14), often reported without co-occurring oncogenic driver mutations, has been identified in 3-4% of NSCLC cases and are associated with poor prognosis (1, 2). The gene discussed is ALK; the disease is non-small cell lung carcinoma.